Femasys
FEMY | NASDAQ
$1.28
-$0.14 (-9.86%)
At close: Nov 16, 2026, 4:00 PM ET
$1.30
+$0.02 (+1.56%)
After-hours:
Nov 16, 2026, 7:30 PM ET
Femasys Company Profile
Company profile explainedCompany Profile
Femasys Inc., a biomedical company established in 2004 and based in Suwanee, Georgia, primarily targets the women's healthcare market within the United States. The firm's innovative product line includes permanent contraceptive solutions such as FemBloc and FemChec, alongside FemaSeed, which is an artificial insemination offering. For diagnostic purposes, Femasys provides FemCerv, a biopsy device utilized for endocervical curettage, and FemEMB, a product candidate intended for endometrial sampling to assist in the detection of uterine cancer. Additionally, the company markets its FemVue saline-air device across various international regions, including the U.S., Europe, Canada, and Japan. Its infertility-related products are supplied to obstetrician-gynecologists, other allied healthcare professionals, women's healthcare provider organizations, and reproductive endocrinologists. The company also offers a range of non-surgical product technologies.
Key Executives
| Name | Position |
|---|---|
| Kathy Lee-Sepsick | Founder, President, Chief Executive Officer & Director |
| Dov Elefant | Chief Financial Officer |
| Jeremy Alexander Sipos | Chief Technology Officer |
| John Canning | Chief Operating Officer |
| James H. Liu | Chief Medical Officer |
| Jeffrey Gerald Mifek | Chief Clinical & Regulatory Affairs Officer |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Oct 15, 2026 | SC 13G | Statement of acquisition of beneficial ownership b... |
| Sep 29, 2026 | 424B3 | Filing |
| Sep 28, 2026 | EFFECT | Filing |
| Sep 03, 2026 | S-3 | Filing |
| Aug 31, 2026 | SC 13G | Statement of acquisition of beneficial ownership b... |
| Aug 20, 2026 | D | Filing |
| Aug 17, 2026 | SC 13D | Filing |
| Aug 14, 2026 | 10-Q | Quarterly Report |
| Aug 14, 2026 | 8-K | Current Report |
| Aug 14, 2026 | SC 13G | Statement of acquisition of beneficial ownership b... |
Femasys
| Country | United States |
| IPO Date | Jun 18, 2021 |
| Industry | Medical - Instruments & Supplies |
| Sector | Healthcare |
| Employees | 53 |
| CEO | Kathy Lee-Sepsick |
Contact Details
3950 Johns Creek Court Suwanee,
Georgia 30024 United States
Stock Details
| Ticker Symbol | FEMY |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001339005 |
| CUSIP Number | 31447E204 |
| ISIN Number | US31447E2046 |
| SIC Code | 3841 |
Add to Watchlist
Select watchlists to add or remove FEMY